Zhejiang Conba Pharmaceutical's subsidiary, Ketoconazole Slow-release Tablets, has obtained a drug registration certificate.
Kanghong Pharmaceutical Co., Ltd. (600572.SH) announced that its wholly-owned subsidiary Hangzhou Kanghong Pharmaceutical Co., Ltd. has recently received the Drug Registration Certificate for Ketotifen Sustained-Release Tablets issued by the National Medical Products Administration. The indication of Ketotifen Sustained-Release Tablets is for peripheral vascular diseases, including intermittent claudication and rest pain.
Zhejiang Conba Pharmaceutical (600572.SH) announced that recently, its wholly-owned subsidiary, Hangzhou Zhejiang Conba Pharmaceutical Co., Ltd., received the "Drug Registration Certificate" approved and issued by the State Food and Drug Administration for its Ketoprofen Slow-release Tablets. The indication for Ketoprofen Slow-release Tablets is for peripheral vascular disease, including intermittent claudication and rest pain.
Related Articles
VALA(02051): Cumulatively delivered 509 vala cars to ordered customers in the second quarter.
VOYAH AUTO (07489): In June, the company delivered 14,223 new cars, a year-on-year increase of 41%.
SHAREHOLDER TONGHUA HIGHTECH PLANS TO REDUCE ITS SHAREHOLDING IN SUZHOU SEPAX TECHNOLOGIES (688758.SH) BY NO MORE THAN 2.5%
VALA(02051): Cumulatively delivered 509 vala cars to ordered customers in the second quarter.
VOYAH AUTO (07489): In June, the company delivered 14,223 new cars, a year-on-year increase of 41%.
SHAREHOLDER TONGHUA HIGHTECH PLANS TO REDUCE ITS SHAREHOLDING IN SUZHOU SEPAX TECHNOLOGIES (688758.SH) BY NO MORE THAN 2.5%
RECOMMEND
